



FOR IMMEDIATE RELEASE

SUSTAINED NANO SYSTEMS APPOINTS MORTON COLEMAN, M.D. DIRECTOR OF MEDICAL ONCOLOGY BOARD.

New York, NY – January 5, 2018 (NEWSFRONT MEDIA). Sustained Nano Systems, LLC (“SNS”), a biopharmaceutical company utilizing bio-resorbable nano and microparticles for long term drug delivery, is pleased to announce the appointment of Morton Coleman, M.D. as Director of its Medical Oncology Board.

With the results of its studies indicating the effectiveness of its Sustained Platform Technology to deliver extended duration of bioactive macromolecules, SNS continues to expand its research efforts. With seven month results indicating in-vivo bioactivity following the single administration of monoclonal antibodies, SNS believes the potential to increase effectiveness of cancer treatment is significant. Dr. Barry Libin, CEO of SNS, points to the leadership of Dr. Coleman in the innovative applications of monoclonal antibodies in cancer therapy, with special interest in lymphoma.

Dr. Coleman is Clinical Professor of Medicine at New York Presbyterian Hospital and a Diplomate in Hematology and Oncology of the American Board of Internal Medicine. He is Associate Director of the Division of Hematology-Oncology and Director of the Center for Lymphoma and Myeloma, at New York Presbyterian-Weill Cornell Medical Center. Dr. Coleman is Associate Editor of the Journal of Clinical Lymphoma, Myeloma & Leukemia, and authored nearly 300 scientific articles, books, and reviews. He received his B.A. from Johns Hopkins University, his M.D. from the Medical College of Virginia School of Medicine, and a Fellow in Hematology at the National Institutes of Health in Hematology. Dr. Coleman’s expertise is in the treatment of lymphoma, myeloma, Waldenstrom’s macroglobulinemia, and associated diseases. He has played an instrumental role in devising the standard treatment for Hodgkin’s disease, the use of infusional chemotherapy in lymphoma, the concept of dose intensity and its use in myeloma and lymphoma, the combined use of thalidomide in myeloma, and the role of PET scanning in lymphoma.

ABOUT SUSTAINED NANO SYSTEMS (SNS)

SNS is a privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions in ophthalmology, oncology and other areas. The Company's research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform is the result of a comprehensive research effort that allows for long term micro-dosing for the continuous release of drugs to targeted tissues as prescribed. The basis of the SNS pipeline is its patented technology that incorporates bio-resorbable nano and micro carriers to deliver a wide variety of drugs that offer both enhanced drug release kinetics and high dose capacity. Such drug delivery is especially needed in ophthalmology, oncology, inflammatory conditions, neurologic disorders, and dermatology. SNS may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support its research and development programs.

For further information, visit: www.sustainednanosystems.net

Forward-Looking Statements

SNS Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:

Dr. Barry Libin
[\(516\) 353-7983](tel:(516)353-7983)
barlibin@gmail.com

Media Relations
info@newsfrontmedia.com

You are subscribed to Sustained Nano Systems, LLC Investor Relations e-mail alerts:
To unsubscribe please send to info@newsfrontmedia.com